Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK 9.76
-0.24 (-2.40%)
Sep 4, 2026, 5:29 PM CET
Xbrane Biopharma AB Market Cap
Xbrane Biopharma AB has a market cap or net worth of 206.05 million as of September 4, 2026. Its market cap has decreased by -71.18% in one year.
Market Cap
206.05M
Enterprise Value
220.27M
Revenue
83.30M
Ranking
n/a
PE Ratio
n/a
Stock Price
9.76
ChartMarket Cap Chart
Since February 3, 2016, Xbrane Biopharma AB's market cap has increased from 131.05M to 206.05M, an increase of 57.23%. That is a compound annual growth rate of 4.37%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 3, 2026 | 206.05M | -1.96% |
| Dec 30, 2025 | 210.17M | -14.54% |
| Dec 30, 2024 | 245.94M | -17.28% |
| Dec 29, 2023 | 297.31M | -86.83% |
| Dec 30, 2022 | 2.26B | -13.94% |
| Dec 30, 2021 | 2.62B | 58.03% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| IRLAB Therapeutics AB | 256.08M |
| Isofol Medical AB | 241.33M |
| Elicera Therapeutics AB | 190.87M |
| Alzinova AB | 172.24M |
| Abera Bioscience AB | 166.04M |
| Initiator Pharma | 160.18M |
| Diamyd Medical AB | 159.63M |
| NextCell Pharma AB | 139.03M |